patients with poor ovarian response. Certain conditions originating in the perinatal period
Conditions
Interventions
Intervention 1: Interventional group: Metoclopramide 10 mg 4 times/day (pre prandial and at the bed side) The drug started 4 weeks before starting IVF cycle and continued till triggering with HCG. Int
Treatment - Drugs
Placebo
Interventional group: Metoclopramide 10 mg 4 times/day (pre prandial and at the bed side) The drug started 4 weeks before starting IVF cycle and continued till triggering with HCG.
Control group: similar placebo effect drugs with the same dose. (pre prandial and at the bed side) The drug started 4 weeks before starting IVF cycle and continued till triggering with HCG.
Sponsors
Vice Chancellor for Medical Sciences Research of Shiraz University
Eligibility
Sex/Gender
Female
Age
40 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: previous treatment using conventional protocols that yield less than 3 oocytes, abnormal ovarian reserve tests as AMH<0.5-1. 1ng/ml or AFC <5-7 Follicles, age over 40 years or any other risk factor that decrease the ovarian reserve such as previous ovarian surgery, genetic problems, chemotherapy, radiotherapy and autoimmune disease, having 2 or more of above factors (Bologna criteria). Exclusion criteria: not have above factors, no agreement of patient, she can not complete the coarse of treatment, become OHSS. (ovarian hyperstimulation syndrom)
Exclusion criteria
Exclusion criteria:
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Clinical pregnancy or spontanous abortion. Timepoint: 7-12 weeks after embryo transfering. Method of measurement: Serum BHCG and TVS. | — |
Primary
| Measure | Time frame |
|---|---|
| Quality and number of ovum and embryo have received in each IVF cycle. Timepoint: On day of ovum pick up and embryo transfer. Method of measurement: Measuring number and quality of oocyte on the day of pick up in lab by embryologist under microscope (GV,MI,MII) and quality of embryo also by the same embryologist according to kind of cell division (grade I,II,III,IV). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Pardis Bakhshaeie
Shiraz Unicversity of Medical Sciences
Outcome results
None listed